Compare Cassava Sciences Inc (FLNA) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Kroger Co — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Kroger Co trades at $57.14 (market cap $34.65B). The key difference: Kroger Co is far larger — about 652.1× Cassava Sciences Inc's market cap, and Kroger Co pays a 2.24% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | KR | |
|---|---|---|
Market Cap | $53.14M | $34.65B |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $75.60 |
52-Week Low | $1.09 | $55.53 |
Enterprise Value | -$33.43M | $54.75B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Kroger (KR) trades at $58.74, down 0.96% today, with a bearish technical outlook despite recent earnings beats. The company maintains stable revenue around $147B with improving net margins to 1.81% in 2025. Recent acquisition of Giant Eagle for $1.65 billion expands Midwest presence, while Berkshire Hathaway ownership provides institutional confidence. Valuation shows mixed signals with low P/S of 0.28 but elevated P/E of 55.29.
KR offers defensive exposure with dividend yield support, but faces competitive grocery wars and margin pressure. Analyst consensus targets $68.63 (17% upside) with 48% buy ratings. Key risks include integration execution of Giant Eagle deal and industry pricing pressures. Cash flow strength supports dividend sustainability despite negative ROE.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
